Application form: tablets, capsules
Indication group: antiarthrotics
Active substance: Chondroitini natrii sulfas 400 mg v jedné tvrdé tobolce.
minimum amount for dispatch: CONDROSULF : Chondroitinsulphate is one of the main parts of the cartilage intercellular mass, and it has a significant characteristic ability to bind water in tissues. Thus it secures the mechanical and elastic properties of cartilage. In arthritic degenerative processes, the content of chondroitinsulphate in cartilage decreases by the effect of specific lytic enzymes. In consequence of the reduced ability to bind water, the gradual cartilage degeneration and deterioration of the joint function deterioration occurs. Administration of Condrosulf 400 leads to renewal of the metabolic balance of chondrocytes by supplying the chondroitinsulphate. The preparation is used in degenerative joint diseases, especially in gonarthrosis, coxarthrosis and in finger joint arthrosis. The preparation is intended for adult patients.
Manufacturer: IBSA Institut Biochimique SA, Lugano, Switzerland, www.ibsa.ch